ArticleNeuropsychiatric disease and treatment2026
Kaempferide Promotes Neuroprotection and Functional Recovery After Spinal Cord Injury and is Associated with Differential Regulation of ARG1, CA4, CYP1B1, and OAT.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Spinal cord injury (SCI) is a severe neurological disorder that often causes long-term motor dysfunction, and effective neuroprotective treatments remain limited. Kaempferide has anti-inflammatory and neuroprotective activities, but its effects and associated targets in SCI remain unclear. Methods: Kaempferide-related targets were intersected with differentially expressed genes and SCI-associated modules from GSE151371. Three machine-learning algorithms identified candidate genes, which were evaluated in GSE151371 and GSE226238. Immune cell deconvolution analysis, gene set enrichment analysis, and molecular docking were performed. The effects of kaempferide were evaluated in glutamate-injured HT22 cells and primary cortical neurons and in a mouse spinal cord hemisection model. CYP1B1 overexpression and siRNA-ARG1 knockdown were used for functional evaluation. Results: Four candidate hub genes-ARG1, CA4, CYP1B1, and OAT-were identified. In GSE151371, their areas under the receiver operating characteristic curves (AUCs) were 0.946, 0.892, 0.926, and 0.913, respectively. In GSE226238, the corresponding AUCs were 0.733, 0.745, 0.871, and 0.823. Molecular docking predicted docking scores of -7.1, -7.7, -10.6, and -8.2 kcal/mol for ARG1, CA4, CYP1B1, and OAT, respectively. Kaempferide increased neurite length and branching in glutamate-injured primary cortical neurons and reduced intracellular ROS accumulation in glutamate-injured HT22 cells. CYP1B1 overexpression and ARG1 knockdown each attenuated kaempferide-enhanced neurite outgrowth. In SCI mice, kaempferide treatment was associated with improved locomotor function, less histological tissue disorganization, and greater NeuN immunoreactivity at the lesion site. Western blotting showed further upregulation of ARG1 and downregulation of CA4, CYP1B1, and OAT after kaempferide treatment. Conclusion: Kaempferide showed neuroprotective effects in cellular and mouse SCI models. CYP1B1 overexpression and ARG1 knockdown experiments supported their potential involvement in kaempferide-enhanced neurite outgrowth, whereas the causal roles of CA4 and OAT remain to be established.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.